Boundless Bio Inc
BOLD1.200USD
+0.040+3.45%
시장 운영 시간 （ET）시세는 15분 지연됩니다
26.76M시가총액
손실P/E TTM
자세한 내용은 Boundless Bio Inc 회사
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells.
회사 정보
종목 코드 BOLD
회사 이름Boundless Bio Inc
상장일Mar 28, 2024
CEOMr. Zachary D. Hornby
직원 수64
유형Ordinary Share
회계 연도 종료Mar 28
주소10955 Alexandria Way
도시SAN DIEGO
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호92121
전화18587669912
웹사이트https://boundlessbio.com/
종목 코드 BOLD
상장일Mar 28, 2024
CEOMr. Zachary D. Hornby
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board
Chairman of the Board
653.48K
--
Mr. Zachary D. Hornby
Mr. Zachary D. Hornby
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Fabio Pucci, Ph.D.
Dr. Fabio Pucci, Ph.D.
Director
Director
--
--
Dr. Christian (Chris) Hassig, Ph.D.
Dr. Christian (Chris) Hassig, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Mr. David Hinkle
Mr. David Hinkle
Principal Financial Officer, Principal Accounting Officer, Treasurer
Principal Financial Officer, Principal Accounting Officer, Treasurer
--
--
Dr. James G. (Jamie) Christensen, Ph.D.
Dr. James G. (Jamie) Christensen, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Doebele
Mr. Robert (Bob) Doebele
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jakob Loven, Ph.D.
Dr. Jakob Loven, Ph.D.
Director
Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Director
Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board
Chairman of the Board
653.48K
--
Mr. Zachary D. Hornby
Mr. Zachary D. Hornby
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Fabio Pucci, Ph.D.
Dr. Fabio Pucci, Ph.D.
Director
Director
--
--
Dr. Christian (Chris) Hassig, Ph.D.
Dr. Christian (Chris) Hassig, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Mr. David Hinkle
Mr. David Hinkle
Principal Financial Officer, Principal Accounting Officer, Treasurer
Principal Financial Officer, Principal Accounting Officer, Treasurer
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, May 14
마지막 업데이트: Wed, May 14
주주
주주 유형
주주
주주
비율
Fidelity Management & Research Company LLC
14.08%
ARCH Venture Partners
12.03%
RA Capital Management, LP
9.74%
Bayer HealthCare LLC
7.22%
Nextech Invest, Ltd.
5.49%
Other
51.44%
주주
주주
비율
Fidelity Management & Research Company LLC
14.08%
ARCH Venture Partners
12.03%
RA Capital Management, LP
9.74%
Bayer HealthCare LLC
7.22%
Nextech Invest, Ltd.
5.49%
Other
51.44%
주주 유형
주주
비율
Investment Advisor
27.63%
Venture Capital
21.89%
Investment Advisor/Hedge Fund
11.86%
Hedge Fund
8.31%
Corporation
7.22%
Individual Investor
4.18%
Research Firm
0.51%
Pension Fund
0.10%
Bank and Trust
0.08%
Other
18.22%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
128
18.31M
81.78%
-1.81M
2025Q1
129
19.49M
87.25%
+660.31K
2024Q4
119
19.41M
87.06%
+540.27K
2024Q3
106
19.47M
87.42%
+538.85K
2024Q2
87
20.07M
90.11%
+1.04M
2024Q1
53
20.35M
91.48%
+20.35M
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Fidelity Management & Research Company LLC
3.15M
14.08%
-187.23K
-5.61%
Mar 31, 2025
ARCH Venture Partners
2.69M
12.03%
--
--
Apr 25, 2025
RA Capital Management, LP
2.18M
9.74%
--
--
Mar 31, 2025
Bayer HealthCare LLC
1.62M
7.22%
--
--
Apr 25, 2025
Nextech Invest, Ltd.
1.23M
5.49%
--
--
Mar 31, 2025
Citadel Advisors LLC
830.94K
3.71%
+40.30K
+5.10%
Mar 31, 2025
Redmile Group, LLC
725.20K
3.24%
-15.00K
-2.03%
Mar 31, 2025
Sectoral Asset Management Inc.
678.57K
3.03%
--
--
Mar 31, 2025
Lim (Jonathan E)
653.48K
2.92%
--
--
Apr 25, 2025
BlackRock Institutional Trust Company, N.A.
587.40K
2.62%
-9.12K
-1.53%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
비율0%
Proshares Ultra Russell 2000
비율0%
iShares Russell 2000 ETF
비율0%
iShares Russell 2000 Value ETF
비율0%
iShares Micro-Cap ETF
비율0%
ProShares UltraPro Russell2000
비율0%
ProShares Hedge Replication ETF
비율0%
iShares Russell 2000 Growth ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
